ONCOSEM ONKOLOJIK SISTEMLER SANAYI VE TICARET ANONIM SIRKETI

Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.Ş. is a Türkiye-based medical device and healthcare technology manufacturer established in Ankara in 2008. With in-house capabilities covering R&D, product development, manufacturing, quality control, technical service, and field operations, Oncosem develops and delivers its technologies both in Türkiye and across international markets.

Oncosem is also a publicly traded company listed on Borsa Istanbul under the ticker ONCSM. 

Oncosem’s product portfolio includes IVEIN needle-free valves and connection systems, IV and extension sets, infusion technologies, chemotherapy drug preparation and administration systems, medical waste management systems, medical connection components, and a wide range of consumables. 

Oncology and chemotherapy technologies represent one of Oncosem’s long-standing areas of expertise. The Company provides automated and controlled chemotherapy drug preparation systems, administration sets, and related consumables to a significant number of oncology centers in Türkiye. Monolitik MC-2, OncoCare Plus, and OncoWaste/M-Waste are among the Company’s key technology platforms in this field.

One of Oncosem’s rapidly growing international product groups is IVEIN, a broad portfolio of needle-free valves, connectors, and IV extension sets developed for different clinical requirements. IVEIN products are used both in Türkiye and in international markets, and Oncosem has been selected as a supplier under the NHS Supply Chain Needle-free Connection Systems framework in the United Kingdom.

Today, Oncosem focuses its efforts across Europe, the United Kingdom, the Middle East, the Gulf region, North Africa, Eastern Europe, and other international markets. The Company works through a combination of distributor partnerships, direct sales, hospital projects, technical service, training, and direct operational models in selected markets.

As part of its international structure, Oncosem has direct corporate presence and local operations in the United Kingdom and Poland. In addition, commercial and operational structures are being developed in several other markets, including Germany and Saudi Arabia. As part of its longer-term global growth strategy, the Company is also planning to establish a direct presence in North America.

Quality and regulatory compliance are fundamental components of Oncosem’s international activities. The Company operates in accordance with ISO 13485:2016 and ISO 9001 quality management systems and holds CE conformity for relevant product groups. The necessary MHRA registration processes for the United Kingdom market have also been completed. In addition, depending on the product and target market, Oncosem manages the relevant product registration, certification, and market-access processes required by regulatory authorities across the United States, the Middle East, North Africa, Europe, and Asia.

To strengthen its international brand visibility and develop global business partnerships, Oncosem regularly participates in leading healthcare and medical technology exhibitions. Key international events include WHX Dubai / Arab Health, MEDICA Düsseldorf, and FIME Florida, in addition to international congresses and meetings focused on oncology, infusion technologies, and medical devices.